Piotech (SH:688072) 2 1 Shi Ji Jing Ji Bao Dao·2025-11-20 14:16Group 1: Pharmaceutical Developments - Fosun Pharma's subsidiary has received breakthrough therapy designation for its PD-1 monoclonal antibody, Surulintinib, for gastric cancer treatment, marking a significant milestone as no other PD-1 targeted monoclonal antibody has been approved for this indication globally [1] - Surulintinib is already approved in China, the EU, and the UK for various cancers, including non-small cell lung cancer and esophageal squamous cell carcinoma [1] Group 2: Supply Agreements - EVE Energy has signed a procurement framework agreement with Simor International for battery cell supplies from 2026 to 2028, although the agreement does not specify financial amounts [1] - The actual financial impact will depend on future orders and will not significantly affect the company's performance in 2025 [1] Group 3: Corporate Actions - Huarong Chemical has not yet introduced clients in the photolithography or photolithography machine sectors, focusing instead on potassium hydroxide and chlorine products for semiconductor and photovoltaic applications [2] - Xunji Technology plans to transfer certain PCB manufacturing assets to its wholly-owned subsidiary and will inject 49.9 million yuan into the subsidiary to support its operations [3] - TuoJing Technology's major shareholder plans to reduce its stake by up to 3% through block trading, with a reduction period set from December 2025 to March 2026 [4] Group 4: Market Activities - Moer Thread has announced a public offering of 70 million shares at a price of 114.28 yuan per share, aiming to raise approximately 8 billion yuan, with a net amount expected to be around 7.576 billion yuan after expenses [5] - Hefu China has experienced a significant stock price increase, with a cumulative rise of 291.92% over a short period, leading to potential market volatility and a possible request for trading suspension [6]